Stiolto is called Spiolto in Europe.
Information about Stiolto (Tiotropium / Olodaterol)
Stiolto (Tiotropium/Olodaterol) is a combination inhalation medication used primarily for the treatment of chronic obstructive pulmonary disease (COPD). It combines two active ingredients: Tiotropium, a long-acting muscarinic antagonist (LAMA), and Olodaterol, a long-acting beta-agonist (LABA). Together, these ingredients help open the airways, improve breathing, and reduce symptoms of COPD. Stiolto is typically administered via a special inhaler device.
Product Highlights
- It is used to manage symptoms and improve airflow in adults with COPD, including chronic bronchitis and emphysema.
- It is not intended for acute relief of sudden breathing problems or asthma attacks.
Key Ingredients
Key Benefits
- The combination of Tiotropium and Olodaterol provides complementary mechanisms to relax the airway muscles and improve airflow in COPD patients.
- Both medications in Stiolto work for up to 24 hours, offering once-daily dosing for convenient management of symptoms.
- Reduces shortness of breath, wheezing, and coughing associated with COPD.
- Helps decrease the frequency and severity of COPD flare-ups, leading to improved quality of life for patients.
- Stiolto is administered through a Respimat inhaler, which is designed for ease of use, especially for those with limited hand strength.
Direction of Use
- Stiolto should be inhaled through the Respimat inhaler, once a day, at the same time each day.
- The standard dose is two inhalations from the Respimat device (one dose).
- The patient should be instructed on the correct use of the inhaler, which involves priming the inhaler before first use and following a step-by-step inhalation technique to ensure effective delivery of the medication.
- Stiolto is for maintenance therapy only and should not be used for immediate relief of acute breathing problems.
Safety Concerns
- As a LABA, Olodaterol may cause heart-related side effects, including rapid heart rate (tachycardia), palpitations, or other cardiovascular events.
- In rare cases, inhalation of bronchodilators like Tiotropium and Olodaterol may lead to paradoxical bronchospasm (tightening of the airways), which can be life-threatening.
- Patients with COPD using inhaled medications, especially long-acting bronchodilators, may have an increased risk of pneumonia.
- Tiotropium (a LAMA) can increase the risk of eye problems like glaucoma, and urinary retention, especially in those with existing bladder issues.
- Stiolto is not indicated for asthma and may not be suitable for patients with asthma, particularly those with a history of hypersensitivity to beta-agonists.
Avoid Stiolto (Tiotropium / Olodaterol) If
- If the patient has a known allergy to Tiotropium, Olodaterol, or any component of the Stiolto inhaler, they should avoid using it.
- Stiolto should not be used to treat sudden breathing problems or asthma attacks, as it is not a rescue inhaler.
- Individuals with narrow-angle glaucoma should avoid Stiolto, as Tiotropium can increase intraocular pressure.
- Patients with urinary retention problems, such as those with enlarged prostate or bladder obstruction, should avoid Stiolto, as Tiotropium can worsen these conditions.
- Patients with serious heart conditions such as arrhythmias or heart failure should avoid using Stiolto or use it with caution, due to the risk of cardiovascular side effects.
